Acceleron Offers Update on Externally-Sponsored Clinical Trial of Dalantercept Monotherapy in Ovarian Cancer
September 23, 2014 at 08:33 AM EDT
Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and ...